Meeting Report: cGMP Matters
Barbara Kemp-Harper1* and
Robert Feil2
1Department of Pharmacology and Centre for Vascular Health, Monash University, Clayton, Victoria, Australia.
2Interfakultäres Institut für Biochemie, Universität Tübingen, Tübingen, Germany.
A report on the 3rd International Conference on cGMP Generators, Effectors and Therapeutic Implications, Dresden, Germany, 15 to 17 June 2007.
Abstract:
The second messenger cyclic guanosine 3',5'-monophosphate (cGMP) controls many cellular functions ranging from growth to contractility. Generated from guanylyl cyclases in response to natriuretic peptides or nitric oxide, cGMP transduces its effects through a number of cGMP effectors, including cGMP-regulated phosphodiesterases and protein kinases. Drugs that modulate cGMP levels are emerging as promising therapies, particularly for cardiovascular disorders. This report summarizes new data on the molecular mechanisms, (patho)physiological relevance, and therapeutic potential of the cGMP signaling system that were presented at the 3rd cGMP meeting held in June 2007 in Dresden, Germany.
*Corresponding author. E-mail: Barbara.Kemp{at}med.monash.edu.au
